[go: up one dir, main page]

PE20110207A1 - Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes - Google Patents

Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes

Info

Publication number
PE20110207A1
PE20110207A1 PE2011000019A PE2011000019A PE20110207A1 PE 20110207 A1 PE20110207 A1 PE 20110207A1 PE 2011000019 A PE2011000019 A PE 2011000019A PE 2011000019 A PE2011000019 A PE 2011000019A PE 20110207 A1 PE20110207 A1 PE 20110207A1
Authority
PE
Peru
Prior art keywords
methyl
methanocinoline
tetrahydrospiro
diaza
cyclopropane
Prior art date
Application number
PE2011000019A
Other languages
English (en)
Inventor
Jean Ackermann
Kurt Amrein
Bernd Kuhn
Alexander V Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20110207A1 publication Critical patent/PE20110207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE TETRAHIDROCINOLINA DE FORMULA (I) DONDE A ES CRaRb O -CH2-CH2-; R1 Y R2 SON H O ALQUILO C1-C8 LINEAL O RAMIFICADO; R3 ES ALQUILO C1-C8, CICLOALQUILO C3-C8, ARILO, ENTRE OTROS; Ra ES H O METILO; Rb ES H O METILO; Ra Y Rb JUNTO AL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN CICLOPROPILO, CICLOBUTILO O CICLOPENTILO, CON LA CONDICION DE QUE SI Ra Y Rb SON H O METILO AL MISMO TIEMPO ENTONCES R3 ES (1-METIL-CICLOPROPIL)METILO. SON COMPUESTOS PREFERIDOS: (5'RS,8'SR)-3'-(2,2-DIMETILPROPIL)-5',6',7',8'-TETRAHIDROESPIRO[CICLOPROPANO-1,9'-[1',2']DIAZA[5',8']METANOCINOLINA], (5'RS,8'SR)-3'-TERT-BUTIL-5',6',7',8'-TETRAHIDROESPIRO[CICLOPROPANO-1,9'-[1',2']DIAZA[5',8']METANOCINOLINA], (5'RS,8'SR)-3'-[(1-METILCICLOPROPIL)METIL]-5',6',7',8'-TETRAHIDROESPIRO[CICLOPROPANO-1,9'-[1',2']DIAZA[5',8']METANOCINOLINA], ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA 11BETA-HIDROESTEROIDE-DESHIDROGENASA-1 (11b-HSD1) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS, DIABETES TIPO II, OBESIDAD, HIPERTENSION, DISLIPIDEMIAS, ENTRE OTRAS
PE2011000019A 2008-07-15 2009-07-06 Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes PE20110207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08160446 2008-07-15

Publications (1)

Publication Number Publication Date
PE20110207A1 true PE20110207A1 (es) 2011-03-31

Family

ID=41050326

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000019A PE20110207A1 (es) 2008-07-15 2009-07-06 Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes

Country Status (17)

Country Link
US (1) US8501940B2 (es)
EP (1) EP2313375A1 (es)
JP (1) JP5575762B2 (es)
KR (1) KR20110036579A (es)
CN (1) CN102089287B (es)
AR (1) AR072803A1 (es)
AU (1) AU2009272895A1 (es)
BR (1) BRPI0915862A2 (es)
CA (1) CA2730059A1 (es)
CL (1) CL2011000061A1 (es)
IL (1) IL209723A0 (es)
MX (1) MX2011000226A (es)
PE (1) PE20110207A1 (es)
RU (1) RU2541533C2 (es)
TW (1) TW201006802A (es)
WO (1) WO2010006940A1 (es)
ZA (1) ZA201009182B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201502527UA (en) * 2012-10-05 2015-04-29 Rigel Pharmaceuticals Inc Gdf-8 inhibitors
TW201609665A (zh) * 2013-11-05 2016-03-16 赫孚孟拉羅股份公司 作為ＲＯＲｃ調節劑的嗒衍生物
CN107635971A (zh) * 2015-05-04 2018-01-26 豪夫迈·罗氏有限公司 作为RORc调节剂的哒嗪衍生物
CN107531669B (zh) * 2015-05-04 2020-12-18 豪夫迈·罗氏有限公司 作为RORc调节剂的哒嗪衍生物
WO2016177760A1 (en) * 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag PYRIDAZINE DERIVATIVES AS RORc MODULATORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423381B1 (en) * 2001-09-06 2007-01-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2003207717B9 (en) * 2002-02-01 2009-05-07 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
NZ534712A (en) * 2002-02-19 2006-11-30 Ono Pharmaceutical Co Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
ATE469886T1 (de) * 2002-11-18 2010-06-15 Schering Corp 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
JP4787321B2 (ja) * 2005-07-05 2011-10-05 エフ．ホフマン−ラ ロシュ アーゲー ピリダジン誘導体
RU2417989C2 (ru) 2006-07-05 2011-05-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЛКИЛПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ 11β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1 (11β-HSD1)

Also Published As

Publication number Publication date
KR20110036579A (ko) 2011-04-07
US8501940B2 (en) 2013-08-06
US20100016325A1 (en) 2010-01-21
CA2730059A1 (en) 2010-01-21
CN102089287A (zh) 2011-06-08
IL209723A0 (en) 2011-02-28
JP5575762B2 (ja) 2014-08-20
TW201006802A (en) 2010-02-16
CL2011000061A1 (es) 2011-07-01
RU2011105058A (ru) 2012-08-20
MX2011000226A (es) 2011-02-24
AR072803A1 (es) 2010-09-22
JP2011528003A (ja) 2011-11-10
EP2313375A1 (en) 2011-04-27
RU2541533C2 (ru) 2015-02-20
ZA201009182B (en) 2011-10-26
AU2009272895A1 (en) 2010-01-21
BRPI0915862A2 (pt) 2015-11-03
WO2010006940A1 (en) 2010-01-21
CN102089287B (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
PE20110207A1 (es) Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
MY146087A (en) Tricyclic compound, compositions, and methods
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
MX2010008040A (es) Derivados de pirimidina 5-fluoro como fungicidas.
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
GEP201706728B (en) Noxious organism control agent
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR111813A2 (es) Compuestos y composiciones para el control de nematodos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
SV2010003642A (es) Compuestos
CO6382126A2 (es) Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas
CL2012000768A1 (es) Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales.
EA201300052A1 (ru) [1,8]нафтиридиновые производные
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
WO2008057855A9 (en) Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
JO2885B1 (en) Protein kinase inhibitors
EA201100210A1 (ru) Аналоги пиридона и пиридазона как модуляторы gpr119
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
CO6260009A2 (es) Derivados de ariloxiacetamida bi-o triciclicos saturados e insaturados y su uso como fungicidas
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.

Legal Events

Date Code Title Description
FC Refusal